Leishmania infantum-induced primary and challenge infections in rhesus monkeys (Macaca mulatta): a primate model for visceral leishmaniasis

R. Porrozzo\textsuperscript{a}, M.S. Pereira\textsuperscript{a}, A. Teva\textsuperscript{a}, A.C. Volpini\textsuperscript{a}, M.A. Pinto\textsuperscript{b}, R.S. Marchevsky\textsuperscript{c}, A.A. Barbosa Jr\textsuperscript{d}, G. Grimaldi Jr\textsuperscript{a,∗}

\textsuperscript{a} Departamento de Imunologia, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro RJ, 21045-900, Brazil
\textsuperscript{b} Departamento de Virologia, Instituto Oswaldo Cruz, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro RJ, 21045-900, Brazil
\textsuperscript{c} Laboratório de Neurovirulência, Instituto de Tecnologia em Imunobiológicos, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro RJ, 21045-900, Brazil
\textsuperscript{d} Unidade de Histopatologia, Centro de Pesquisas Gonçalo Moniz, FIOCRUZ, Salvador, BA, Brazil

Received 1 September 2005; received in revised form 3 November 2005; accepted 3 November 2005
Available online 7 February 2006

KEYWORDS
Visceral leishmaniasis; Leishmania infantum; Macaca mulatta; Immune responses; Histopathology; Treatment

Summary  Visceral leishmaniasis (VL) was experimentally induced in rhesus macaques (Macaca mulatta) by intravenously inoculating $2 \times 10^7$ amastigotes/kg of body weight of Leishmania infantum. The macaques developed a systemic disease showing characteristic features of human VL such as fever, diarrhoea, body weight loss, anaemia, hypergammaglobulinaemia and transient lymphocytosis, as well as lymph node, liver and/or spleen enlargement. Nine weeks after infection, one primate showed pronounced weight loss, became moribund and was euthanized. The necropsy findings included granulomas composed of parasite-containing macrophages, lymphocytes and plasma cells in the liver, spleen and lymph nodes. The remaining macaques had a sustained course of infection but developed a mild-to-moderate illness that subsequently showed evidence of self-cure. Of note, pathological findings included a typical cell-mediated immunity-induced granulomatous reaction that had an effect on the control of parasite replication. All infected monkeys responded with increased production of anti-Leishmania-specific IgG antibodies. Despite the fact that clinical resistance to L. infantum was not consistently associated with a parasite-specific cell-mediated immune response, drug-cured macaques from the primary infection acquired immunity to homologous re-infection. These findings point to the feasibility of using the L. infantum macaque model for pre-clinical evaluation of novel chemotherapeutics or vaccine candidates for human VL.

© 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
1. Introduction

Leishmaniasis is one of the major infectious diseases affecting mainly the poorest regions of the world. Among the two million new human infections annually in the 88 countries where the disease is endemic, 500,000 cases are clinical visceral leishmaniasis (VL); excluding epidemics, there are 57,000 deaths annually worldwide (www.who.int/tb/diseases). Concerns about treatment failure for VL are exacerbated by geographical variation in antimicrobial treatment regimens, severity of disease and sensitivity of Leishmania species, and no proven successful vaccine for controlling human leishmaniasis is in routine use (Davies et al., 2003).

The protozoa Leishmania donovani and L. infantum (syn. L. chagasi) are the causative agents of VL. The incidence is rising with urbanisation and HIV co-infection (Desjeux, 2001). Leishmania infantum VL is a zoonotic disease found in Latin America, Europe, Asia and Africa. In the Neotropics, the parasite is usually transmitted by the sandfly Lutzomyia longipalpis, and domestic dogs are the principal reservoir hosts. Control programmes in Brazil focus on residual insecticide spraying and mass elimination of seropositive dogs, but these conventional measures are costly and fail in developing countries (Courtenay et al., 2002).

The artificial induction of protective immunity using second-generation vaccines against leishmaniasis (Coler and Reed, 2003) would be essential for ultimate control of the disease. Nevertheless, there is still much to be done in assessing the effectiveness of vaccination in the absence of a natural challenge. Clinical development of the vaccine comprising the polyprotein Leish-111f in the adjuvant MPL-SE (Coler and Reed, 2005) may not be fully protective across Leishmania species. Another vaccine candidate of specific interest is HASPB1, a recombinant stage-specific hydrophilic acylated surface protein that protects against experimental L. donovani LV9 in mice (Stager et al., 2000).

Non-human primates are physiologically close to humans (Kennedy et al., 1997) and will probably mimic human response to L. donovani complex parasites. Indeed, different Old World monkeys and Neotropical simian species have become useful in studying the biology of infection and in dissecting the host response to these parasites. Those reported as being highly susceptible to this group of pathogens include New World primates such as the owl monkey Aotus trivirgatus (Broderson et al., 1986; Chapman et al., 1981), the squirrel monkey Saimiri sciureus (Chapman and Hanson, 1981; Dennis et al., 1985, 1986) and the marmoset Callithrix jacchus jacchus (Marsden et al., 1981). All of these species have since been used as non-human primate models of VL for antileishmanial chemotherapy studies (Berman et al., 1986; Madindou et al., 1985). East African primate species such as Sykes monkeys (Cercopithecus mitis) and baboons (Papio cynocephalus) all supported low-grade L. donovani infections for periods ranging between 4 and 8 months and subsequently showed evidence of self-cure (Githure et al., 1986). Furthermore, disease mimicking human VL was established in Indian langur monkeys Presbytis entellus (Dube et al., 1999) as well as in vervet monkeys Cercopithecus aethiops (Binhazim et al., 1993; Gicheru et al., 1995). The L. donovani—langur monkey model was also explored to assess different vaccine formulations against VL (Dube et al., 1998; Misra et al., 2001).

In our studies, L. amazonensis (Amaral et al., 1996), L. major (Amaral et al., 2001) and L. braziliensis (Teva et al., 2003) infections in outbred rhesus macaques produced cutaneous leishmaniasis (CL) of variable severity (ranging from self-healing granulomatous cutaneous lesions to non-healing mucocutaneous disease) and the immunological findings were similar to those observed in human CL. The homology between the Macaca mulatta immune system (Giavedoni, 2005; Pahar et al., 2003) and that of humans has led to the belief that the efficacy of those antigens selected as being candidates for an anti-Leishmania vaccine in this animal model (Campos-Neto et al., 2001; Kenney et al., 1999) may represent suitable vaccine candidates against this parasite in humans. The present studies on infections with L. infantum in macaques were performed to develop an animal model for human VL that would optimise progression of vaccine candidates to phase I trials. The parallels found between humans and this primate species with regard to susceptibility, clinicopathological changes and specific immunological responses to L. infantum visceral infections are not surprising given their close phylogenetic relationship (Kennedy et al., 1997), thus providing an acceptable model for the purpose of vaccine evaluation.

2. Material and methods

2.1. Animals

Colony outbred (Andrade et al., 2004a), young adult (weighing 6–10 kg) male rhesus macaques (M. mulatta) from the Fiocruz Primate Research Centre (Rio de Janeiro, Brazil) were used in this study. Primates were housed individually in stainless-steel squeeze-back cages and fed daily with a commercially available primate diet supplemented with fresh fruits and vegetables. Water was provided ad libitum. Syrian golden hamsters (Mesocricetus auratus) were also used in this study as the donor source of the inoculums. The experimental protocols involving monkeys and hamsters were reviewed and approved by the Institutional Animal Care and Use Committee (CEUA-Fiocruz, resolution # P0048-00). Primates were acclimatised to the laboratory conditions for at least 2 weeks before the experimental procedures began; they were monitored daily by non-human primate care specialists and evaluated by a veterinarian. When necessary (before infection and prior to each sampling or testing procedure), the animals were anaesthetised with 10–20 mg ketamine hydrochloride (Vetalar™)/kg of body weight injected intramuscularly.

2.2. Experimental infections

The strain (MHOM/BR/2000/1669) of L. infantum originally isolated from the bone marrow of a Brazilian patient with active VL was maintained by hamster-to-hamster passage. The parasite was typed by multilocus enzyme electrophoresis (Cupolillo et al., 1994) in our laboratory before being used for infection. For experimental infections, amastigotes harvested from heavily infected hamster spleens were prepared...
according to the procedure as previously described (Amaral et al., 1996).

A study was first designed to provide information regarding the virulence of the infecting parasite. Six of the seven naïve macaques were each inoculated via the saphenous vein with 2 × 10^7 amastigotes/kg of body weight. One monkey, designated as the control, was injected with uninfected hamster spleen homogenate. An additional study was designed to evaluate the level of clinical resistance to the homologous challenge. These same macaques that had recovered from VL following treatment with meglumine antimoniate (at a dosage of 20 mg of Sbp/kg/day, given intramuscularly for 28 days; therapy start at week 37 after infection) were each subsequently challenged via the saphenous vein with 2 × 10^8 amastigotes/kg at week 60 post inoculation (PI).

2.3. Assessment of infection and disease development

Once every 2 weeks, all macaques underwent gross physical examination and body weight, blood samples and rectal temperature were taken from each monkey through the duration of the experiment. Monkeys were examined for six typical signs of human VL (fever, diarrhoea, body weight loss, lymphadenopathy, hepatomegaly and splenomegaly). Following the procedure described by Courtenay et al. (2002), each sign was scored on a semiquantitative scale from 0 (absent) to 3 (severe) and these scores were added together to give an overall clinical score. Monkeys with a total score of 0–2 were arbitrarily classed as asymptomatic, those with a score of 3–6 were classified as oligosymptomatic and those with a score of 7–18 were classified as polysymptomatic.

Heparin- or EDTA-anticoagulated blood samples were collected by venipuncture for haematological and immunological studies. Blood collected into tubes containing EDTA as an anticoagulant was used for a complete haemogram. The following blood components were measured with a computer-directed analyser, using commercially available kits (CELM^TM^ Cia Equipadora de Laboratórios Modernos, Barueri, SP, Brazil): cholesterol, urea nitrogen, total protein and albumin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Total erythrocyte, leukocyte and haemoglobin counts were carried out with the cellular counter 530/550 (CELM^TM^ Cia Equipadora de Laboratórios Modernos). Haematocrit values were performed according to standard procedures, including Wright’s coloration, which was used for blood films. Commercial assays were conducted in accordance with the manufacturer’s instructions. Total plasma proteins were determined with a refract meter (American Optical T/C, Scientific Instrument Division, Buffalo, NY, USA). The plasma protein patterns of each monkey were determined by cellulose acetate electrophoresis using a Modular Electrophoresis System (Roche Laboratories, Basel, Switzerland).

For assessment of parasites, biopsy specimens were removed from bone marrow, liver and spleen at distinct stages of infection and processed for DNA isolation and culture or histological examination. For PCR analysis, liver and spleen specimens from the uninfected monkey were included as negative controls. Biopsy samples were cultured using NNN blood agar medium overlaid with Schneider’s Drosophila insect medium (Sigma, St Louis, MO, USA) supplemented with 20% (v/v) heat-inactivated fetal calf serum (HI-FCS) and 100 µg/ml gentamicin (complete Schneider’s medium). One macaque that developed very severe disease was euthanized with sodium pentobarbitone (Euthanol®). Gross and light microscopic examinations of the major organs were performed at necropsy. Paraffin sections from biopsy and necropsy tissues samples (fixed in 10% neutral buffered formalin) were stained with haematoxylin–eosin.

2.4. Diagnosis by DNA analysis

The PCR methods followed for detection of Leishmania DNA in infected monkeys have been described previously (Volpini et al., 2004). Briefly, DNA purification from 10–20 mg biopsy fragments of liver, spleen or bone marrow was done using the Wizard® Genomic DNA Purification System (Promega, Madison, WI, USA) following the manufacturer’s instructions. Primers were designed to amplify the conserved region of the minicircle of Leishmania kDNA producing genus-specific fragments of 120 bp (Degrase et al., 1994). The reaction was carried out using 1 µM of each primer (150: 5’ GGG(G/T)AGGGCCCTTCT(C/G)CGAA 3’; and 152: 5’ (C/G)(C/G)(C/G)(A/T)CTAT(A/T)TTACACCAACCCC 3’) together with 200 µM of dNTPs, 0.8 U of Taq DNA polymerase (Invitrogen, São Paulo, Brazil), buffer (10 mM Tris—HCl pH 8.6, 50 mM KCl, 1.5 mM MgCl2) and 2 µl of DNA template in a final volume of 25 µl. Amplification was carried out in an MJ Research PTC-200 machine (MJ Research Inc., Watertown, MA, USA) using an initial denaturing step at 95 °C for 5 min, followed by 29 cycles at 95 °C for 1 min, 55 °C for 30 s, 72 °C for 10 s and a final extension step of 5 min. Each experiment included a positive control (100 fg of Leishmania kDNA) and a negative control with no DNA. The expected amplification products of 120 bp were analysed by 8% polyacrylamide gel (Promega, Madison, WI, USA). The reaction was revealed with biotin–avidin peroxidase system. The substrate consisted of 0.04% 3,3′-diaminobenzidine tetrahydrochloride and 0.02% hydrogen peroxide in 0.025 M Tris–HCl, pH 7.6, and stained using a DNA Silver Staining Kit (Amersham Biosciences, Buckinghamshire, UK) to visualise the bands. All PCR-negative results were tested for reaction inhibitors by doing a negative control with no DNA. The expected amplification products of 120 bp were analysed by 8% polyacrylamide gel (Promega, Madison, WI, USA). The reaction was revealed with biotin–avidin peroxidase system. The substrate consisted of 0.04% 3,3′-diaminobenzidine tetrahydrochloride and 0.02% hydrogen peroxide in 0.025 M Tris–HCl, pH 7.6, and stained using a DNA Silver Staining Kit (Amersham Biosciences, Buckinghamshire, UK) to visualise the bands. All PCR-negative results were tested for reaction inhibitors by doing a negative control with no DNA.

2.5. Antigens

Promastigotes of L. infantum (MHOM/BR/2000/1669) provided the source of the antigens. A preparation of soluble leishmanial antigens (SLA) was made as described previously (Amaral et al., 2001). The SLAs were used at different concentrations for ELISA and in vitro blast transformation assays.

2.6. ELISA for antiparasitic antibodies

Serum from the monkeys was analysed by adapting a standard ELISA technique (Amaral et al., 2001) to detect parasite-specific antibodies (using a peroxidase conjugate rabbit anti-monkey immunoglobulin G; Sigma, St Louis, MO, USA). The reaction was revealed with biotin–avidin peroxidase system. The substrate consisted of 0.04% 3,3′-diaminobenzidine tetrahydrochloride and 0.02% hydrogen peroxide in 0.025 M Tris–HCl, pH 7.6, and stained using a DNA Silver Staining Kit (Amersham Biosciences, Buckinghamshire, UK) to visualise the bands. All PCR-negative results were tested for reaction inhibitors by doing a negative control with no DNA.
of horseradish peroxidase–streptavidin conjugate at a concentration of 1:2000 in PBS. Reaction was developed using tetramethylbenzidine as the substrate. Cytokine concentrations for unknown samples and controls were read from the plotted standard curve.

2.9. Statistical analysis

Student’s t-test was used in comparative analysis and a P-value of <0.05 was considered statistically significant. Concordance between cellular immune responses was assessed as reported elsewhere (Amaral et al., 2001).

3. Results

3.1. Establishment of infection and disease development

*Leishmania infantum* primary infection in outbred macaques was assessed through time by parasitological examination or PCR of the liver, spleen and bone marrow. All of the monkeys had established infection by week 2 PI and parasites persisted in lymphoid organs as long as 25 weeks PI, except for the monkey (O45) that recovered spontaneously from VL (Table 1). Overall, attempts to detect parasite-positive specimens by culture (61%; 14/23) were more successful than PCR (53%; 17/32) and direct microscopic examination (50%; 9/18). However, there was variation in the sensitivity of each diagnostic test following the time course of infection. Considering only macaques positive for *Leishmania* DNA by PCR, the sensitivity of the test was high (90.9%; 10/11) during active infection, but lower (20%; 2/10 samples) in the self-healing phase and after antimony therapy.

Table 2 shows that a similar picture to human VL, characterised by systemic disease of varying severity, develops in *L. infantum*-infected monkeys. According to their clinical condition, two macaques (N13 and O59) with a total score of 10 and 7, respectively, and four others (O45, O21, F14, O43) with scores of 4–6 were classed as polysymptomatic and oligosymptomatic, respectively. The most consistent clinical parameters were an intermittent rise in body temperature by 2–4 °C, diarrhoea and body weight loss. These changes were evident by week 2 PI and became more pronounced during the first 4 months of infection. Although visceral organ enlargement was seen as a result of the experimental infection, no animal showed a syndrome similar to human VL with progressive hepatosplenomegaly.

Nine weeks after infection, one primate (N13) developed a severe illness after losing 42% of his body weight. At this time he was anorectic, listless and became weak and dehydrated, and was euthanized. Gross necropsy findings included enlarged spleen (five-fold), mesenteric lymph nodes and fatty liver. The surviving five chronically infected macaques lost between 7% and 28% of their body weight. These primates clinically recovered from infection following antimony-based therapy and regained normal weight by week 45 PI. At this time, the weight of the uninfected control monkey (O15) increased by 5%. Of note, in the second experiment we found that the same macaques were refractory to the disease (as indicated by complete clinical resistance).
Table 1  Comparative results of conventional diagnostic procedures and PCR of Leishmania infantum visceral infection in rhesus macaques (Macaca mulatta)

<table>
<thead>
<tr>
<th>Monkey</th>
<th>Time PI (weeks)</th>
<th>Clinical status (stage)</th>
<th>Demonstration of the parasite (biopsy specimen)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Histological sections&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>O15</td>
<td>0</td>
<td>Uninfected control</td>
<td>n.d.</td>
</tr>
<tr>
<td>N13</td>
<td>2</td>
<td>Oligosymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Polysymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Polysymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td>O59</td>
<td>2</td>
<td>Oligosymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Polysymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Polysymptomatic (healing)</td>
<td>− (BM); − (L)</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>Asymptomatic (drug-cured)</td>
<td>n.d.</td>
</tr>
<tr>
<td>F14</td>
<td>2</td>
<td>Oligosymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Polysymptomatic (active)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Polysymptomatic (healing)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>Asymptomatic (drug-cured)</td>
<td>n.d.</td>
</tr>
<tr>
<td>O43</td>
<td>2</td>
<td>Oligosymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Polysymptomatic (active)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Polysymptomatic (healing)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>Asymptomatic (drug-cured)</td>
<td>n.d.</td>
</tr>
<tr>
<td>O21</td>
<td>2</td>
<td>Oligosymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Polysymptomatic (active)</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Polysymptomatic (active)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>Asymptomatic (drug-cured)</td>
<td>n.d.</td>
</tr>
<tr>
<td>O45</td>
<td>2</td>
<td>Oligosymptomatic (active)</td>
<td>+ (L)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Polysymptomatic (active)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Asymptomatic (healing)</td>
<td>− (L)</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>Asymptomatic (drug-cured)</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

PI: post inoculation; BM: bone marrow; L: liver; S: spleen; +: positive; −: negative; n.d.: not done.
<sup>a</sup> Haematoxylin–eosin stain.
<sup>b</sup> Each experiment included positive and negative controls (see Section 2.4).

3.2. Haematology and blood chemistry

The results for the haematological parameters evaluated in the rhesus macaques prior to and at different time points after *L. infantum* challenge infections are given in Table 3. The pre-infection mean blood counts were within the normal range compared with the baseline haematological data previously found for clinically healthy rhesus macaques from the Fiocruz colony (Andrade et al., 2004b). The most consistent haematological finding was a normochromic, normocytic anaemia. An appreciable fall in the red blood cell (RBC) count occurred from week 2 PI onward, and the count was minimal at 46 weeks PI. Packed cell volumes and haemoglobin levels paralleled the RBC values, but exhibited a wide variation. White blood cell counts also varied during infection. Whilst the haemogram revealed neutrophilia and lymphopenia by 9 weeks PI, neutropenia, eosinophilia and lymphocytosis were detected at week 15 PI. Alterations in serum chemistries of infected macaques included increases in blood urea nitrogen, total protein and globulin. Of note, in at least three of these macaques the plasma concentration of gamma globulins increased from a pre-inoculation mean value of 0.3 g/dl to 0.8 g/dl at week 9 PI (Table 2). Typical changes are also illustrated in Figure 1.

One monkey (N13) that had severe disease showed significantly altered haematological values. The RBC values decreased from a pre-infection value of 5.695 × 10<sup>6</sup> /ml to 3.300 × 10<sup>6</sup> /ml by 6 weeks PI. Packed cell volumes and haemoglobin levels decreased from 38% and 13.3 g/dl at pre-infection to 20% and 7.4 g/dl, respectively, at 6 weeks PI. The leukocyte count reduced from an initial value of 6.20 × 10<sup>3</sup> /ml to 1.90 × 10<sup>3</sup> /ml. At this time, the levels of AST (72 IU/l) or ALT (88 IU/l) were elevated, but the cholesterol level declined (108 mg/dl) in this animal.

3.3. Histopathological findings

Hepatic granulomas were found in all infected macaques. Granulomas were formed as early as 2 weeks PI and persisted as active in some monkeys through at least 33 weeks PI. The poorly differentiated granulomas of the initial infection consisted primarily of widespread macrophages (some of which contained amastigotes) and variable numbers of...
Table 2  Clinical outcome of experimental *Leishmania infantum* visceral leishmaniasis in rhesus macaques (*Macaca mulatta*)

<table>
<thead>
<tr>
<th>Clinical and laboratory features of sick macaques⁴</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N13*</td>
</tr>
<tr>
<td>Overall clinical score⁵</td>
<td>10</td>
</tr>
<tr>
<td>Fever</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2</td>
</tr>
<tr>
<td>Decrease in body weight (% change)</td>
<td>3 (42)</td>
</tr>
<tr>
<td>Enlarged lymph nodes</td>
<td>1</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>2</td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>1</td>
</tr>
</tbody>
</table>

**Leishmania** in biopsy specimens⁶

- Overall clinical score: data presented as pre-infection value, followed by the minimum and maximum values obtained during the time course of infection in parentheses.
- Plasma concentration of γ-globulins (g/dl)⁷
- Leishmania-specific serum IgG (OD value)⁷,⁸
- Leishmanin skin test (mm)⁹
- Specific lymphoproliferative response (SI)⁹,¹⁰
- IFN-γ levels in culture supernatants (pg/ml)⁹,¹⁰
- IL-5 levels in culture supernatants (pg/ml)⁹,¹⁰

---

⁴ Each macaque was inoculated intravenously with a single dose of $2 \times 10^7$ amastigotes/kg of body weight. *This monkey developed fulminating disease and was therefore euthanized at week 9 post infection. At necropsy, the spleen was enlarged five-fold.

⁵ Monkeys were scored for six typical signs of human visceral leishmaniasis as described in Section 2.3.

⁶ For assessment of parasites, biopsy specimens were removed from bone marrow, liver and spleen at distinct stages of infection and then processed for *Leishmania* DNA, culture and histological examinations (see Table 1). Figures in parentheses are the number of weeks following infection.

⁷ Data presented as pre-infection value, followed by the minimum and maximum values obtained during the time course of infection in parentheses.

⁸ Antigen-specific antibody concentrations were determined by ELISA and results are expressed as the optical density (OD) at 492 nm (see Figure 3).

⁹ Delayed-type hypersensitivity reactions to *Leishmania* antigens are expressed as the mean diameter of skin induration and were considered positive if ≥5 mm. Figures in parentheses are the number of weeks after infection.

¹⁰ Lymphocyte proliferation in response to parasite antigen was expressed as stimulation index (SI) and was considered positive if ≥3 (see Section 2.8).

---

* Measurement of cytokine secretion in the supernatants of antigen-stimulated cultures was assayed by ELISA (see Section 2.8).
### Table 3: Comparative haematological data in rhesus macaques (Macaca mulatta) prior to and after primary and challenge Leishmania infantum infections\(^a,b\)

<table>
<thead>
<tr>
<th>Week post infection(^c)</th>
<th>RBC (x10^12/ml)</th>
<th>Hct (%)</th>
<th>Hb (g/dl)</th>
<th>TLC (x10^3/ml)</th>
<th>Bas. (%)</th>
<th>Eos. (%)</th>
<th>Neu. (%)</th>
<th>Mon. (%)</th>
<th>Lym. (%)</th>
<th>AST (IU/l)</th>
<th>ALT (IU/l)</th>
<th>Cholest. (mg/dl)</th>
<th>Urea nitrogen (mg/dl)</th>
<th>Total protein (g/dl)</th>
<th>Albumin (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0(7)</td>
<td>5.66±0.24</td>
<td>38.2±2.8</td>
<td>13.3±0.63</td>
<td>5.51±2.63</td>
<td>0.0±0.0</td>
<td>0.7±0.9</td>
<td>61.0±2.5</td>
<td>3.5±1.5</td>
<td>29.3±3.8</td>
<td>27.0±6.5</td>
<td>42.1±2.2</td>
<td>176.0±38.1</td>
<td>17.8±3.8</td>
<td>5.37±0.35</td>
<td>3.38±0.26</td>
</tr>
<tr>
<td>2(5)</td>
<td>4.33±0.24</td>
<td>38.2±2.8</td>
<td>12.8±0.5</td>
<td>5.36±4.07</td>
<td>0.0±0.0</td>
<td>2.2±0.7</td>
<td>63.4±12.5</td>
<td>5.6±1.7</td>
<td>29.2±4.4</td>
<td>36.4±12.3</td>
<td>35.6±11.3</td>
<td>190.0±24.0</td>
<td>27.8±6.3</td>
<td>5.72±0.35</td>
<td>3.64±0.33</td>
</tr>
<tr>
<td>6(3)</td>
<td>4.59±0.35</td>
<td>36.2±2.4</td>
<td>14.9±0.4</td>
<td>5.78±3.17</td>
<td>0.0±0.0</td>
<td>4.0±0.4</td>
<td>60.6±2.6</td>
<td>3.4±1.7</td>
<td>30.0±3.8</td>
<td>42.0±10.6</td>
<td>101.2±17.9</td>
<td>28.0±11.6</td>
<td>5.34±0.44</td>
<td>3.80±0.40</td>
<td>3.16±0.50</td>
</tr>
<tr>
<td>9(5)</td>
<td>5.00±0.35</td>
<td>35.6±2.5</td>
<td>12.1±0.9</td>
<td>4.58±1.37</td>
<td>0.0±0.0</td>
<td>3.0±1.9</td>
<td>69.4±3.5</td>
<td>2.2±0.9</td>
<td>23.4±5.2</td>
<td>28.8±12.4</td>
<td>183.4±24.0</td>
<td>18.0±5.2</td>
<td>5.38±0.55</td>
<td>3.64±0.41</td>
<td>3.16±0.50</td>
</tr>
<tr>
<td>15(5)</td>
<td>5.00±0.19</td>
<td>36.0±1.4</td>
<td>12.2±0.4</td>
<td>6.42±1.66</td>
<td>0.4±0.5</td>
<td>8.4±5.7</td>
<td>43.4±8.3</td>
<td>5.4±2.7</td>
<td>41.6±7.2</td>
<td>33.2±16.4</td>
<td>198.0±23.2</td>
<td>25.8±11.7</td>
<td>5.36±0.65</td>
<td>3.78±0.38</td>
<td>3.16±0.50</td>
</tr>
<tr>
<td>33(5)</td>
<td>4.74±0.47</td>
<td>34.8±2.9</td>
<td>11.9±0.8</td>
<td>6.86±1.15</td>
<td>0.0±0.0</td>
<td>0.8±0.8</td>
<td>55.8±11.3</td>
<td>4.2±0.4</td>
<td>38.6±11.6</td>
<td>46.0±23.7</td>
<td>52.2±28.9</td>
<td>159.0±51.7</td>
<td>35.4±12.6</td>
<td>5.36±0.41</td>
<td>3.48±0.40</td>
</tr>
<tr>
<td>46(5)</td>
<td>4.30±0.36</td>
<td>36.0±2.2</td>
<td>12.2±0.7</td>
<td>7.04±1.54</td>
<td>0.0±0.0</td>
<td>0.8±0.8</td>
<td>69.8±10.1</td>
<td>2.8±1.6</td>
<td>25.0±8.9</td>
<td>22.3±11.4</td>
<td>38.8±27.7</td>
<td>108.0±20.7</td>
<td>43.8±16.6</td>
<td>7.00±1.15</td>
<td>3.50±0.63</td>
</tr>
<tr>
<td>60(5)</td>
<td>4.16±0.44</td>
<td>37.6±1.8</td>
<td>12.7±0.2</td>
<td>5.20±0.87</td>
<td>0.2±0.4</td>
<td>0.4±0.9</td>
<td>52.6±10.5</td>
<td>5.2±2.8</td>
<td>40.4±11.7</td>
<td>32.6±8.7</td>
<td>106.0±27.0</td>
<td>36.0±12.7</td>
<td>4.92±1.00</td>
<td>2.96±0.51</td>
<td>3.16±0.50</td>
</tr>
<tr>
<td>65(5)</td>
<td>4.95±0.39</td>
<td>36.8±2.9</td>
<td>12.5±1.0</td>
<td>5.80±1.47</td>
<td>0.0±0.0</td>
<td>0.4±0.9</td>
<td>62.4±14.2</td>
<td>3.5±1.5</td>
<td>34.4±14.8</td>
<td>18.8±3.6</td>
<td>25.2±3.2</td>
<td>115.0±12.1</td>
<td>26.6±7.1</td>
<td>6.22±0.40</td>
<td>3.96±0.50</td>
</tr>
<tr>
<td>76(5)</td>
<td>7.33±0.93</td>
<td>36.4±2.5</td>
<td>12.9±2.0</td>
<td>6.64±6.29</td>
<td>0.0±0.0</td>
<td>0.8±0.8</td>
<td>60.6±2.9</td>
<td>5.6±1.1</td>
<td>32.0±2.9</td>
<td>25.2±2.2</td>
<td>120.0±16.1</td>
<td>31.9±4.6</td>
<td>6.38±0.60</td>
<td>3.84±0.28</td>
<td>3.16±0.50</td>
</tr>
</tbody>
</table>

\(^a\) Statistically significant differences between pre- and post-infection mean values (except for macaque N13, which was a complete outlier from the rest of the group) are indicated by \(P<0.05\) or \(P<0.01\) (Student’s unpaired t-test).

\(^b\) Each macaque was inoculated intravenously with a single dose of 2 x 10^7 amastigotes/kg of body weight. Cured primates (following treatment with meglumine antimoniate at 20 mg SDY/kg, given intramuscularly for 30 days) were re-challenged with 2 x 10^8 amastigotes/kg at week 60 post infection.

\(^c\) Values are expressed as the mean ± SD.

\(\) Figures in parentheses are the number of analysed samples.

---

**3.5. Cell-mediated immune responses**

A very high degree of variability was observed in the parasite-specific recall immune responses in primates before the challenge. Four animals (O9, F14, O43 and O45) converted to a positive proliferative response in primates before the challenge, four animals (O59, F14, O43 and O45) converted to a positive proliferative response after infection (data not shown). The parasitemic-specific recall proliferative response in primates before the challenge (Figure 4A). Of note, one oligosymptomatic monkey (O21) demonstrated a specific proliferative response (SI value of 27.5) only by week 76 PI.

**3.4. Humoral responses**

As shown in Figure 3, the antibody response detected by ELISA in macaques infected with Leishmania infantum. The parasite-specific antibodies, continuing up to 76 weeks PI. Interestingly, the antibodies directed against the same L. infantum antigens were not consistently higher compared with the non-infected controls (N3 and O45) after the challenge, as well as compared to the positive proliferation test results (Figure 2A and D). These granulomas contained less marked proliferating and macrophages (forms of which contained the vacuolated cells in the adjacent cells) were also observed in the spleen and bone marrow (data not shown). Sections of the spleen and bone marrow. This infiltration of lymphoid cells, associated with diffuse fibrosis and granulomas, was also observed in the spleen and bone marrow. In addition, CD3-positive cells were not found in sections at this time.
Significant but varying levels of IFN-γ were secreted in PBL cultures from all the infected macaques when stimulated with either PHA (data not shown) or SLA (Table 2; Figure 4B). In the uninfected control monkey (O15), IFN-γ was only detected when PBLs were stimulated with PHA. Noteworthy, a strong Leishmania-specific IFN-γ response was elicited in the rhesus monkey (N13) that had the most protracted fatal course of infection. In contrast, either PHA- (data not shown) or SLA-induced IL-5 secretion in supernatant fluids was at low or undetectable levels (Table 2; Figure 4C). Comparison of immune responses in terms of antigen-specific IFN-γ production with the blastogenic response of PBLs from infected macaques showed that there was no positive correlation between the results of the two assays ($r^2 = 0.038; P = 0.1453$).

4. Discussion

Typically, L. infantum VL affects young children and immunocompromised adults. The disease can have a long incubation period and has been reported to present as a smouldering subclinical illness characterised by weight loss, fever and diarrhoea that can evolve either into a self-healing or full-blown disease (Evans et al., 1995). The clinical features of VL in humans include intermittent fever, progressive emaciation, anaemia, lymphadenopathy and hepatosplenomegaly. Although malnutrition is a risk factor for the development of human VL, our understanding of the pathogenesis of the disease is still rudimentary.

Non-human primates have varying degrees of susceptibility to L. donovani complex parasites. The results of this study revalidate original reports (Manson-Bahr and Wilson, 1976; Shortt, 1923) identifying M. mulatta as a moderately susceptible host to L. donovani complex parasites. In the original model description (Shortt, 1923), induced fulminating infections were regarded as exceptions rather than the rule. Likely, macaques in this study had a sustained course of L. infantum visceral infection, ranging from mild self-curing to severe disease. The macaques lost between 7% and 42% of their body weight and developed progressive liver lesions as revealed by the granulomatous inflammatory reaction studied chronologically after infection. Hepatomegaly and splenomegaly were difficult to evaluate in monkeys surviving the disease, but the post-mortem findings detected in rhesus N13 included a five-fold enlarged spleen.

The major haematological changes (anaemia associated with haemosiderosis and tissue iron deposition) in rhesus macaques with VL paralleled the haemolysis associated with hypersplenism observed to occur in humans with VL (Cartwright et al., 1948) and other infected monkey species (Binhazim et al., 1993; Broderson et al., 1986; Dennis et al., 1985). Moreover, one monkey (N13) that had severe disease showed a significant increase in the levels of AST and ALT, indicating liver disorders. The hepatic lesions resolved following drug-induced recovery from the disease, confirming the antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime®) in the rhesus monkey model (Teva et al., 2005).

Sensitive molecular techniques have allowed the identification of leishmanial parasites directly in scars after clinical cure of L. (L.) braziliensis CL in patients (Schubach et al., 1998) and in experimentally infected macaques (Teva et al., 2003). By contrast, whereas persistence of L. infantum parasites was documented in all monkeys during active infection, no parasites were found (using either conventional diagnostic procedures or PCR for detecting Leishmania DNA) after treatment. Whether exposure to a particular parasite has led to sterile cure could not be ascertained by this study. The ability of Leishmania to establish latency in immune individuals is evidence of parasite determinants to escape the host’s immune response by clonal
selection or molecular changes resulting from mutational or recombinational processes. Of note, our genotyping analyses showing genetic variations among L. (L.) braziliensis isolates from humans and experimentally infected macaques (Teva et al., 2003) indicated that persistent parasites do not retain the characteristics of the parental clones.

It should be noted that our model is artificial in the sense that intravenous injection of a large number of amastigotes initiates the infection, which may account for the parasitic invasion of lymphopoietic organs with the resulting chronic granulomatous inflammatory response that was observed. Descriptions of the histopathological lesions in the liver either of patients with VL (Sen Gupta et al., 1956) or of experimentally infected L. donovani macaques (Manson-Bahr and Wilson, 1976) resemble the granulomas described here. The hepatic granulomas in this study were most prominent 2–9 weeks PI and had an effect on the control of parasite replication. Of note, the marked regression of immune granulomas and the eventual absence of parasites 25 weeks PI correlated with satisfactory resolution of the disease.

Figure 2 Photomicrographs of the liver and spleen from a rhesus macaque (N13) 9 weeks after inoculation with Leishmania infantum. (A,B) Sections showing multifocal coalescing hepatic immune granulomas consisting of an aggregation of activated macrophages (epithelioid cells) and multiple Langhans-type giant cells (arrows), surrounded by lymphocytes, at the portal spaces, which obliterate the sinusoids and protrude the parenchyma. (C,D) Also illustrated are the proliferation and hyperplasia of parasite-laden Kupffer cells (double arrow), associated with fatty changes of the stellate cells (arrowheads). (E,F) Sections from the spleen showing granulomas consisting of differentiated macrophages in the pulp, with widespread macrophages aggregating in the cords and walls of dilated medullary sinuses. Numerous haemosiderin deposits are present (arrows). (H&E stain; bar scale = 10 μm.)
This type of immune response capable of creating a protective granuloma (Murray, 2001) is firmly linked to the IL-12-dependent IFN-γ production pathway (Lammas et al., 2002).

Whilst the generation of anti-Leishmania antibodies apparently plays no role in resistance to leishmaniasis, a strong cell-mediated immune response is essential. The protective immune response in mice against L. major is dependent on the ability to mount an IL-12-driven T-helper cytokine type 1 (Th1) response, which activates infected macrophages by production of IFN-γ for the killing of intracellular parasites (Alexander and Bryson, 2005). Vaccine efficacy against Leishmania is also thought to be largely associated with the emergence of a specific Th1 response (Coker and Reed, 2005). In humans, whilst there is a good correlation between Th1 responses and resistance to CL, no association between increased IL-4 and kala-azar has been identified (Kharazmi et al., 1999). However, a direct correlation between production of IL-10 and active disease is reported in patients with VL (Ghalib et al., 1993). One could speculate that the exacerbation of disease observed in macaque N13 could be due to the suppressor activity of IL-10-secreting CD4+CD25+ regulatory T-cells (Belkaid et al., 2002).

In the present study, L. infantum-specific antibodies in serum were detected by ELISA in all infected animals; levels of IgG antibodies rose during active infection and then declined during treatment, but they increased after re-challenge infection. Positive DTH responses were seen in most of the resistant monkeys with self-limiting disease when skin tested with leishmanin at 21 weeks after infection, whereas the control uninfected monkey and one monkey (N13) with progressive illness did not respond. Skin test reactivity following natural exposure is also thought to reflecting resistance to infection, with genetic epidemiology studies (Shaw et al., 1995) demonstrating a strong genetic component for mounting a skin test response to leishmanial antigen.

We have also used conventional in vitro assays of cellular immunity to understand some of the mechanisms that underlie resistance to L. infantum. The cytokines of interest were primarily selected because of their importance as markers for Th1 or Th2 immune responses or inflammatory responses. The anti-human IL-5 mAb evaluated in this study has been used previously for ELISA detection of
macaque IL-5 (Måkitalo et al., 2002). In our experiments, the antigen-stimulated cells produced IL-5 at low or undetectable levels, whereas production was slightly enhanced by PHA stimulation. This, and the finding (Måkitalo et al., 2002) of the poor cross-reactivity displayed by the mAbs to cynomolgus and rhesus macaque IL-5, highlight the need for a thorough investigation of mAb cross-reactivity. Our results confirmed some studies on the basic immunological parameter in M. mulatta (Pahar et al., 2003), showing that the magnitude and kinetics of lymphocyte proliferation in response to antigen is not directly related to effector or T-cell functions such as secreted IFN-γ.

Despite the fact that clinical healing was not consistently linked with an abundance of antigen-specific IFN-γ-producing cells, animals that recovered from previous infection acquired immunity to homologous re-infection. This was also the situation in vaccinated monkeys (Campos-Neto et al., 2001; Kenney et al., 1999) in which neither pre-challenge in vitro antigen-specific recall T-cell proliferative and IFN-γ responses nor positive DTH response were predictive of clinical protection. Taken together, this confirms the importance of quantitative assessment of low-frequency, antigen-specific T-cells from rhesus macaques by ELISPOT and cytokine flow cytometry assays (Pahar et al., 2003), as well as using luminex technology (Giavedoni, 2005), to determine correlates of protection against leishmanial infection. Finally, the demonstration of a specific immunological response in L. infantum-infected macaques, such as described here, suggests that this primate model of human VL should be of practical importance since it shows several features underlying immunity that could be met by an effective vaccine.

Conflicts of interest statement
The authors have no conflicts of interest concerning the work reported in this paper.

Acknowledgements
We thank Dr Antonio da Mota Marinho and the staff in the Fiocruz Animal Care Facility for their assistance with daily care and procedures on the macaques. Financial support was received from Fiocruz; PRONEX 3/CNPq (Brazil) and the Millennium Institute for Vaccine Development and Technology (CNPq-420067/2005-1).

References


Misra, A., Dube, A., Srivastava, B., Sharma, P., Srivastava, J.K., Kati-

Murray, H.W., 2001. Tissue granuloma structure–function in experiment-


Teva, A., Porrozzi, R., Cupolillo, E., Oliveira-Neto, M.P., Grimaldi Jr, G., 2005. Responses of *Leishmania (Viannia) braziliensis* cuta-

Volpini, A.C., Passos, V.M.A., Oliveira, G.C., Romanha, A.J., 2004. PCR-RFLP to identify *Leishmania (Viannia) braziliensis* and *L. (Leishmania) amazonensis* causing American cutaneous leishma-